NCT06054113: An ongoing trial by Amgen
This trial is ongoing. It must report results 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06054113 |
|---|---|
| Title | An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 23, 2024 |
| Completion date | Jan. 5, 2026 |
| Required reporting date | Jan. 5, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |